AR and prostate cancer: Knowing that the steady state concentration of bicalutamide in the serum of prostate cancer patients is 8.9 μg/mL or approximately 20 μM [52], we were surprised to find that in our assay this drug activated the wild-type AR in the same concentrations range (approximately 16 μM) (Additional file 4: Table S2).